ClinVar Miner

Submissions for variant NM_000142.5(FGFR3):c.1620C>A (p.Asn540Lys) (rs28933068)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 14
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000255928 SCV000321638 pathogenic not provided 2018-07-19 criteria provided, single submitter clinical testing The N540K pathogenic variant in the FGFR3 gene has been reported previously in the heterozygous state in multiple individuals with hypochondroplasia, as well as achondroplasia (Bellus et al., 1995; Xue et al., 2014). The N540K variant occurs in a tyrosine kinase domain of FGFR3 and functional studies show that this variant results in significantly reduced expression patterns and reduced STAT1 phosphorylation (Raffioni et al., 1998; Krejci et al., 2008). The N540K variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. In-silico analyses, including protein predictors and evolutionary conservation, support a deleterious effect. The N540K variant is not observed in large population cohorts (Lek et al., 2016). We interpret N540K as a pathogenic variant.
EGL Genetic Diagnostics, Eurofins Clinical Diagnostics RCV000255928 SCV000337275 pathogenic not provided 2018-06-02 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV000506429 SCV000603707 pathogenic none provided 2019-11-03 criteria provided, single submitter clinical testing The FGFR3 c.1620C>A; p.Asn540Lys variant (rs28933068; ClinVarID: 16337) is reported in the literature in multiple individuals affected with hypochondroplasia and achondroplasia (Bellus 1995, Deutz-Terlouw 1998, Xue 2014). Together with another variant resulting in the same amino acid change (c.1620C>G; p.Asn540Lys), these account for over 50% of all hypochondroplasia cases (Bellus 2000, Linnankivi 2012, Xue 2014). The asparagine at codon 540 is highly conserved, and functional analyses of the variant protein show significant reductions in protein expression and kinase activity (Krejci 2008, Raffioni 1998). Based on available information, this variant is considered to be pathogenic. References: Bellus GA et al. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet. 1995 Jul;10(3):357-9. Bellus GA et al. Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am J Hum Genet. 2000 Dec;67(6):1411-21. Deutz-Terlouw PP et al. Asn540Thr substitution in the fibroblast growth factor receptor 3 tyrosine kinase domain causing hypochondroplasia. Hum Mutat. 1998;Suppl 1:S62-5. Krejci P et al. Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage. PLoS One. 2008;3(12):e3961. Linnankivi T et al. Neuroimaging and neurological findings in patients with hypochondroplasia and FGFR3 N540K mutation. Am J Med Genet A. 2012 Dec;158A(12):3119-25. Raffioni S et al. Effect of transmembrane and kinase domain mutations on fibroblast growth factor receptor 3 chimera signaling in PC12 cells. A model for the control of receptor tyrosine kinase activation. J Biol Chem. 1998 Dec 25;273(52):35250-9. Xue Y et al. FGFR3 mutation frequency in 324 cases from the International Skeletal Dysplasia Registry. Mol Genet Genomic Med. 2014 Nov;2(6):497-503.
Invitae RCV000528114 SCV000640361 pathogenic Craniosynostosis syndrome 2020-01-02 criteria provided, single submitter clinical testing This sequence change replaces asparagine with lysine at codon 540 of the FGFR3 protein (p.Asn540Lys). The asparagine residue is highly conserved and there is a moderate physicochemical difference between asparagine and lysine. This variant is not present in population databases (rs28933068, ExAC no frequency). This variant is one of the most commonly reported causes of sporadic or familial hypochondroplasia (PMID: 7670477, 8589686, 9452043, 25614871). A different variant (c.1620C>G) giving rise to the same protein effect observed here (p.Asn540Lys) is also commonly reported in individuals affected with hypochondroplasia, and together these variants account for 50 to 76% of all cases (PMID: 11055896, 23165795, 25614871). This variant is also known as c.1659C>A in the literature. For these reasons, this variant has been classified as Pathogenic.
CeGaT Praxis fuer Humangenetik Tuebingen RCV000255928 SCV001247234 pathogenic not provided 2018-04-01 criteria provided, single submitter clinical testing
Clinical Genetics Karolinska University Hospital,Karolinska University Hospital RCV000255928 SCV001449694 pathogenic not provided 2017-08-02 criteria provided, single submitter clinical testing
Blueprint Genetics RCV000255928 SCV001832496 pathogenic not provided 2020-01-22 criteria provided, single submitter clinical testing
OMIM RCV000017740 SCV000038018 pathogenic Hypochondroplasia 1999-06-11 no assertion criteria provided literature only
GeneReviews RCV000017740 SCV000086721 pathologic Hypochondroplasia 2013-09-26 no assertion criteria provided curation Converted during submission to Pathogenic.
Clinical Molecular Genetics Laboratory,Johns Hopkins All Children's Hospital RCV000017740 SCV000109626 pathogenic Hypochondroplasia 2015-07-21 no assertion criteria provided clinical testing
Clinical Molecular Genetics Laboratory,Johns Hopkins All Children's Hospital RCV000353403 SCV000692269 pathogenic Achondroplasia 2015-07-21 no assertion criteria provided clinical testing
Bioscientia Institut fuer Medizinische Diagnostik GmbH,Sonic Healthcare RCV000017740 SCV000863901 pathogenic Hypochondroplasia 2018-06-18 no assertion criteria provided clinical testing
Beijing Key Laboratory for Genetic Research of Skeletal Deformity, Peking Union Medical College Hospital RCV000017740 SCV001482319 pathogenic Hypochondroplasia 2019-05-31 no assertion criteria provided research
Human Genetics - Radboudumc,Radboudumc RCV000255928 SCV001951990 pathogenic not provided no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.